Purpose Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer. Lipid–
polymer hybrid nanoparticles (LPNs) combine the advantages of both polymeric …

Purpose Lung cancer is the leading cause of cancer mortality worldwide. Drug resistance is
the major barrier for the treatment of non-small cell lung cancer (NSCLC). The aim of this …

Special targeted therapy like endothelial growth factor receptor (EGFR) targeted therapy is
available for the treatment of advanced non-small cell lung cancer (NSCLC). Biodegradable …

One approach to improve the targeted therapeutic efficiency of lung cancer is to deliver
drugs using nano-scaled systems. In this study, RGD peptide-modified, paclitaxel (PTX) …

Purpose Non-small cell lung cancer (NSCLC) therapy faces the barriers including drug
resistance. A transferrin-functionalized protein-lipid hybrid nanoparticle (PLHN) was …

Context: Paclitaxel (PTX) and doxorubicin (DOX) are widely used for the combined
chemotherapy of solid tumors. However, free drug combination has lower antitumor …

Polymeric nanoparticles and liposomes have been the platform of choice for nanoparticle-
based cancer drug delivery applications over the past decade, but extensive research has …

Cancer represents one of the most dangerous diseases, with 1.8 million deaths worldwide.
Despite remarkable advances in conventional therapies, these treatments are not effective …

The rate of lung cancer in tuberculosis (TB) patients is 7 to 30% higher than that in healthy
individuals. Conventional chemotherapy of lung cancer shows limited efficiency due to poor …

The purpose of this study was to develop a novel lipid–polymer hybrid drug carrier
comprised of folate (FA) modified lipid-shell and polymer-core nanoparticles (FLPNPs) for …